Neurosearch A/s

Boehringer Ingelheim Pharma Kg

Andreas Raschig

Roger Nitsch

Christoph Hock

Klaus Dugi

Joachim Mierau

Thomas Friedl

Marion Wienrich

Klaus Mendla

Klaus Bornemann

Juergen Reess

Cornelia Dorner-Ciossek

Frank Berger

Dieter Horst Meier

Laurence Salin

Jörgen Scheel-Krüger

Jürgen Reess

The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients.

Treatment of type 2 diabetes

Methods of lowering the levels of A&bgr; , A&bgr; and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine, or a physiologically acceptable acid addition salt thereof, and methods of treating diseases associated with the formation of diffuse and senile plaques or A&bgr; -, A&bgr; - and tau-containing plaques are disclosed.

Muscarinic M1 agonist as an inhibitor of beta-amyloid (A&bgr;40 and A&bgr;42)-synthesis

Growing community of inventors

Biberach, Germany

Andreas Raschig